Short Interest Filing: Aclaris Therapeutics Incorporated (NASDAQ:ACRS) Sellers Increased By 5.97% Their Shorts

November 23, 2016 - By Marguerite Chambers   ·   0 Comments

Short Interest Filing: Aclaris Therapeutics Incorporated (NASDAQ:ACRS) Sellers Increased By 5.97% Their Shorts

The stock of Aclaris Therapeutics Incorporated (NASDAQ:ACRS) registered an increase of 5.97% in short interest. ACRS’s total short interest was 596,700 shares in November as published by FINRA. Its up 5.97% from 563,100 shares, reported previously. With 70,100 shares average volume, it will take short sellers 9 days to cover their ACRS’s short positions. The short interest to Aclaris Therapeutics Incorporated’s float is 5.34%. About 12,909 shares traded hands. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 37.94% since April 21, 2016 and is uptrending. It has outperformed by 32.61% the S&P500.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The company has a market cap of $694.67 million. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. It currently has negative earnings. The Company’s lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis , a non-malignant skin tumor.

Aclaris Therapeutics Inc (NASDAQ:ACRS) Ratings Coverage

Out of 4 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Aclaris Therapeutics has been the topic of 8 analyst reports since November 2, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by William Blair given on Monday, November 2. The firm earned “Buy” rating on Monday, November 2 by Jefferies. The rating was initiated by JMP Securities with “Market Perform” on Friday, September 30. The company was maintained on Friday, August 12 by Jefferies. The firm has “Buy” rating given on Monday, November 2 by Citigroup. Guggenheim initiated Aclaris Therapeutics Inc (NASDAQ:ACRS) on Friday, June 10 with “Buy” rating. Jefferies maintained the stock with “Buy” rating in Monday, September 19 report.

ACRS Company Profile

Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications.

More news for Aclaris Therapeutics Inc (NASDAQ:ACRS) were recently published by: Foxbusiness.com, which released: “Why Aclaris Therapeutics, Inc. Stock Is Down Today” on November 17, 2016. Investorplace.com‘s article titled: “3 Stocks to Watch on Wednesday: Aclaris Therapeutics Inc (ACRS), Agilent …” and published on November 16, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>